Populations and Risk Factors
- Any cancer patient may receive chemotherapy, alone or in combination with surgery and/or radiation
- Hematologic malignancies (leukemia, lymphoma, myeloma) often require extended chemotherapy regimens with profound myelosuppression
- Solid tumors (breast, colon, lung, ovarian) commonly receive adjuvant or neoadjuvant chemotherapy
- Elderly patients metabolize drugs more slowly and are more susceptible to side effects
- Patients with pre-existing renal or hepatic impairment clear drugs more slowly, increasing toxicity
- Patients with pre-existing neuropathy (diabetes, alcoholism) are at higher risk for chemotherapy-induced peripheral neuropathy (CIPN)
- Patients with cardiac history are at elevated risk from cardiotoxic agents (anthracyclines)
Causes and Pathophysiology
Mechanism of Action
- Chemotherapy drugs target cells in active division (mitosis). Cancer cells divide more rapidly and less efficiently than normal cells, making them more vulnerable — but any rapidly dividing normal cell is collateral damage.
- Most regimens combine multiple agents targeting different phases of the cell cycle (combination chemotherapy) to improve efficacy and reduce resistance.
Drug Classes and Their Specific Side Effects
| Drug Class | Examples | Mechanism | Key Side Effects for MT |
|---|---|---|---|
| Alkylating agents | Cyclophosphamide, cisplatin | Cross-link DNA strands preventing replication | Myelosuppression, nausea, hemorrhagic cystitis (cyclophosphamide) |
| Antimetabolites | Methotrexate, 5-fluorouracil | Mimic cellular building blocks, disrupt DNA/RNA synthesis | Mucositis, myelosuppression, hepatotoxicity (methotrexate) |
| Plant alkaloids / Mitotic inhibitors | Vincristine, paclitaxel (Taxol) | Disrupt mitotic spindle preventing cell division | Peripheral neuropathy (strongest association — taxanes and vinca alkaloids), myelosuppression |
| Topoisomerase inhibitors | Irinotecan, etoposide | Block enzymes for DNA uncoiling | Myelosuppression, diarrhea |
| Antitumor antibiotics | Doxorubicin, bleomycin | Intercalate DNA, interfere with replication | Cardiotoxicity (doxorubicin — dose-dependent cardiomyopathy), pulmonary fibrosis (bleomycin) |
| Targeted therapies | Trastuzumab (Herceptin), imatinib | Target specific molecular pathways | Cardiotoxicity (trastuzumab), skin reactions, fatigue |
| Checkpoint inhibitors | Pembrolizumab (Keytruda), nivolumab | Activate immune system against cancer | Autoimmune reactions (colitis, hepatitis, skin rash), fatigue |
Myelosuppression — The Critical Safety Concept
- Bone marrow is one of the most rapidly dividing tissues; chemotherapy suppresses all three cell lines:
- Red blood cells (anemia): fatigue, pallor, dizziness, exercise intolerance — reduces treatment tolerance
- White blood cells / neutrophils (neutropenia): infection vulnerability — the absolute neutrophil count (ANC) determines IPAC precautions; ANC <1000 = neutropenic precautions; ANC <500 = severe neutropenia (high infection risk)
- Platelets (thrombocytopenia): bleeding and bruising risk — platelet count determines safe pressure levels
- Nadir: the lowest point of blood counts, typically occurring 7–14 days after each chemotherapy cycle. This is when the patient is most vulnerable.
- Counts typically recover before the next cycle, creating a predictable window of relative safety for massage.
Peripheral Neuropathy (CIPN)
- Plant alkaloids (vincristine, vinblastine) and taxanes (paclitaxel, docetaxel) are the drugs most strongly associated with peripheral neuropathy.
- The mechanism involves disruption of microtubule function in axons — the same mechanism that prevents cancer cell division also impairs axonal transport in peripheral nerves.
- Presents as numbness, tingling, burning, or "pins and needles" in a stocking-glove distribution (feet first, then hands).
- May be partially or completely irreversible — CIPN can persist months to years after chemotherapy ends.
- CIPN reduces sensory feedback during massage, making patient reports of pressure unreliable in affected areas.
Why This Matters for Massage
- Platelet count determines safe pressure: <50,000 = light effleurage only; <20,000 = circulatory massage contraindicated.
- Neutrophil count determines IPAC requirements: neutropenic patients require strict hand hygiene and the therapist must postpone if they have any symptoms of illness.
- Neuropathy zones require pressure modification because the patient cannot provide reliable sensory feedback.
- Fatigue is cumulative and pervasive — session duration must be adapted to the patient's current capacity.
Signs and Symptoms
Hematologic
- Fatigue, pallor, dizziness (anemia)
- Unexplained bruising, petechiae (pinpoint hemorrhages), prolonged bleeding from minor cuts (thrombocytopenia)
- Recurrent or severe infections, slow wound healing (neutropenia)
Neurological
- Peripheral neuropathy: numbness, tingling, burning in hands and feet (stocking-glove pattern)
- "Chemo brain" — cognitive impairment including difficulty concentrating, memory lapses, word-finding difficulty
- Balance and coordination problems from proprioceptive neuropathy
Gastrointestinal
- Nausea and vomiting (most severe 24–48 hours post-treatment; may persist for days)
- Mucositis — painful inflammation and ulceration of oral and GI mucosa
- Diarrhea or constipation depending on the agent
- Anorexia and weight loss
Other
- Alopecia (hair loss — scalp, eyebrows, eyelashes, body hair)
- Skin fragility, dryness, and photosensitivity
- Cardiotoxicity signs (anthracyclines): new dyspnea, peripheral edema, exercise intolerance, chest discomfort
- Radiation recall: inflammatory reaction in a previously irradiated field triggered by certain chemotherapy drugs
Assessment Profile
Subjective Presentation
- Chief complaint: fatigue is the most common complaint; "I'm exhausted all the time and nothing helps"; may also report nausea, neuropathy symptoms (tingling hands/feet), generalized aching, emotional distress, difficulty sleeping
- Pain quality: generalized muscle aching and fatigue-related discomfort; neuropathic pain in hands and feet (burning, tingling, electric sensations); mouth pain from mucositis; bone pain (from colony-stimulating factor injections that stimulate marrow recovery)
- Onset: symptoms correlate with treatment cycle timing — worst during nadir (7–14 days post-treatment), improving as counts recover; cumulative effects worsen with each successive cycle; neuropathy may be progressive over the treatment course
- Aggravating factors: activity (profound fatigue limits tolerance); reclining flat (may worsen nausea); cold temperatures (may worsen neuropathy); abdominal massage (may worsen GI distress during nausea period)
- Easing factors: rest (but fatigue does not fully resolve with rest — cancer-related fatigue is distinct from ordinary tiredness); antiemetics (prescribed for nausea); massage itself has evidence for reducing fatigue, pain, and anxiety in oncology patients; warmth may comfort aching muscles
- Red flags: Fever >38°C (100.4°F) during neutropenic nadir — potential neutropenic sepsis; emergency medical referral. Sudden severe bruising or bleeding — may indicate critically low platelets; medical referral. New shortness of breath, peripheral edema, chest discomfort in a patient receiving anthracyclines — possible cardiotoxicity; medical referral. Sudden unilateral limb swelling — DVT risk is elevated in active cancer; urgent medical referral.
Observation
- Local inspection: pallor (anemia); bruising and petechiae (thrombocytopenia); alopecia (may be partial or complete); mucositis (visible oral ulceration); skin dryness or rash; port or PICC line dressing visible (usually on the chest, upper arm, or antecubital area); general appearance of fatigue (slow movements, drawn features)
- Posture: no characteristic chemotherapy-specific posture, but general deconditioning produces: rounded shoulders, reduced trunk extension, cautious movement pattern; patients with significant neuropathy may have widened base of support for balance
- Gait: may show balance disturbance if proprioceptive neuropathy is significant; cautious, slow gait from fatigue and deconditioning; ataxic pattern if cerebellar involvement (rare with standard agents)
Palpation
- Tone: generalized muscle wasting from deconditioning and catabolic state; may have compensatory tension in postural muscles (upper trapezius, paraspinals) from prolonged rest positions; muscles may feel soft and atrophic rather than hypertonic
- Tenderness: generalized muscle soreness (chemotherapy-related myalgia); bone tenderness (especially after colony-stimulating factor injections — sternum, pelvis, long bones); port site tenderness — never palpate or apply pressure over ports, PICC lines, or central venous catheters; neuropathic areas may be painful to light touch (allodynia) or insensate — assess before treating
- Temperature: skin may be cool from anemia (reduced oxygen-carrying capacity) or warm from low-grade inflammation; during neutropenic fever, generalized warmth with flushing — this is a medical emergency, not a massage scenario; assess for fever before every session during active treatment
- Tissue quality: skin may be thin, dry, and fragile from chemotherapy effects on rapidly dividing skin cells; bruise easily (thrombocytopenia); subcutaneous tissue may be reduced from weight loss; edema in dependent areas from deconditioning and immobility; irradiated areas (if concurrent radiation) have distinct tissue changes (see radiation therapy article)
Motion Assessment
- AROM: generally reduced from deconditioning, fatigue, and general malaise; not typically limited by structural restriction; assess functional capacity rather than formal ROM testing — "how much energy does this person have for movement today?"
- PROM / end-feel: generally normal structural mobility unless other conditions coexist (arthritis, surgical restriction); stiffness from prolonged immobility may produce muscular end-feel; neuropathic patients may not report end-range pain accurately
- Resisted testing: generalized weakness from deconditioning, anemia, and muscle wasting; not diagnostically significant for chemotherapy itself; useful for establishing baseline function and tracking deconditioning over treatment course
Special Test Cluster
The SOT cluster for chemotherapy is oriented toward safety screening (hematologic status, infection risk, device protection) rather than orthopedic diagnosis.| Test | Positive Finding | Purpose |
|---|---|---|
| Blood Count Inquiry (History) (CMTO) | Platelet count <50,000 or ANC <1000; or patient cannot report recent counts and is within 7–14 days of last treatment | Determine safe pressure levels and IPAC requirements; this is the single most important pre-treatment assessment |
| Port/Line Location Check (Visual/Palpation) (CMTO) | Palpable subcutaneous device on chest, arm, or antecubital area; dressing visible | Identify absolute avoidance zones — never apply pressure over ports, PICC lines, or central venous catheters |
| Sensation Screen (Hands and Feet) (CMTO) | Diminished light touch, sharp-dull discrimination, or proprioception in stocking-glove distribution | Identify neuropathic zones where patient feedback is unreliable; guides pressure modification |
| DVT Screen (Visual/History) (CMTO — red flag screen) | Unilateral limb swelling, warmth, tenderness; active cancer is a major DVT risk factor | Red flag — active cancer significantly increases DVT risk; urgent medical referral if positive |
| Nausea/Tolerance Assessment (History) (supplementary) | Active nausea, recent vomiting, inability to recline flat | Guides positioning (semi-reclined preferred), session duration, and technique selection |
| Bruising Screen (Visual) (supplementary) | Unexplained bruising, petechiae, or prolonged bleeding from minor skin breaks | Direct evidence of thrombocytopenia even if platelet count is unknown; reduce pressure or defer treatment |
Platelet count pressure guide: >50,000 = standard pressure appropriate; 50,000–20,000 = light effleurage, holding techniques, gentle compression only; <20,000 = circulatory massage contraindicated (holding, energy work, or presence only). If the count is unknown and the patient is within 7–14 days of treatment, treat as if counts are low.
Differential Assessment
| Condition | Key Distinguishing Feature |
|---|---|
| Neutropenic Sepsis | Fever >38°C during neutropenic nadir with potential rapid deterioration; tachycardia, hypotension, confusion; medical emergency; do not treat; call emergency services |
| Deep Vein Thrombosis | Unilateral limb swelling and tenderness in a patient with active cancer (Virchow's triad: hypercoagulability, stasis, endothelial damage); urgent medical referral |
| Chemotherapy-Induced Cardiotoxicity | New dyspnea, peripheral edema, orthopnea, chest discomfort in a patient on anthracyclines or trastuzumab; medical referral to oncologist/cardiologist |
| Tumor Progression | New or worsening pain, swelling, or neurological symptoms not explained by treatment side effects; weight loss exceeding expected treatment effects; oncologic reassessment |
| Radiation Recall | Inflammatory reaction in a previously irradiated field triggered by certain chemotherapy agents; erythema and desquamation in the radiation field weeks to months after radiation; local contraindication until resolved |
CMTO Exam Relevance
- Chemotherapy causes myelosuppression — the nadir (lowest blood count point) typically occurs 7–14 days post-treatment cycle
- Platelet count thresholds: <50,000 requires reduced pressure; <20,000 contraindicates circulatory massage
- Neutropenia requires strict IPAC; postpone treatment if the therapist has any active illness
- Plant alkaloids (vincristine, paclitaxel/Taxol) are strongly associated with peripheral neuropathy — know this drug class association
- Doxorubicin (an anthracycline / antitumor antibiotic) causes dose-dependent cardiotoxicity (cardiomyopathy)
- Implanted ports and central lines must never receive pressure — absolute avoidance zone
- ANC <1000 = neutropenic precautions; ANC <500 = severe neutropenia with high infection risk
- Chemotherapy side effects (not the cancer) drive most massage modifications — this concept is testable
Massage Therapy Considerations
- Primary therapeutic target: symptom management for treatment side effects — fatigue, pain, anxiety, nausea, and neuropathy; massage provides palliative benefit and quality-of-life improvement rather than treating the underlying cancer
- Sequencing logic: assess hematologic status (blood counts) and treatment timing before planning the session; schedule sessions mid-cycle (when counts have recovered from nadir) for safest treatment; begin with the patient's highest-priority symptom (often fatigue or pain) and adapt as tolerance dictates; keep the session flexible — the patient's condition may change during treatment
- Safety / contraindications: pressure scaled to platelet count (see pressure guide above); strict IPAC if neutropenic — hand hygiene, clean linens, postpone if therapist has any respiratory symptoms, skin infection, or GI illness; never apply pressure over ports, PICC lines, or central venous catheters; avoid deep friction or sustained pressure on neuropathic areas (unreliable feedback); avoid abdominal massage during active nausea; DVT screening essential at every session (active cancer is a major DVT risk factor)
- Timing: best sessions occur mid-cycle when blood counts have recovered; avoid treatment on the day of chemotherapy infusion and the 24–48 hours following (highest nausea and systemic stress)
- Heat/cold guidance: warm applications for comfort (muscle aching, generalized soreness); avoid heat over neuropathic areas with diminished sensation; avoid heat over ports or lines; cool cloths for nausea management (forehead, posterior neck)
- Fatigue management: sessions may need to be shorter (30 minutes or less); the patient may fall asleep during treatment (this is expected and beneficial); monitor continuously for signs of exhaustion; position changes should be minimized to conserve energy
- Alopecia sensitivity: handle the scalp gently; ask permission before touching the head; use fragrance-free products (chemotherapy increases olfactory sensitivity)
Treatment Plan Foundation
Clinical Goals
- Reduce perceived fatigue and improve relaxation and sleep quality
- Decrease anxiety and promote parasympathetic state
- Manage neuropathic symptoms (comfort, not cure — CIPN may be irreversible)
- Address compensatory musculoskeletal discomfort from deconditioning and prolonged rest
Position
- Semi-reclined supine (30–45 degrees) if nausea is a concern — flat supine may worsen nausea
- Side-lying if the patient cannot tolerate semi-reclined or has a port on the anterior chest
- Avoid prone if nausea is active, if port is on the anterior chest, or if the patient is too fatigued for position changes
- Minimize position changes — every transition consumes the patient's limited energy
- Ensure warmth — chemotherapy patients may chill easily from anemia
Session Sequence
- Begin with gentle holding and grounding — hands placed on the shoulders or upper back for 1–2 minutes to establish contact and assess the patient's current state; observe for signs of nausea, fatigue, or distress
- Light effleurage to posterior trunk (if accessible) — slow, rhythmic strokes for parasympathetic activation; assess general tissue quality and note any bruising
- Gentle shoulder and neck work — upper trapezius, cervical paraspinals; address tension from deconditioning postures; very light pressure — monitor for bruising response
- Upper extremity work — light effleurage and gentle compression; avoid the side with port/PICC line — work the contralateral arm only, or maintain a wide safety margin around the device
- Lower extremity work — gentle effleurage from proximal to distal; light pressure; monitor for DVT signs (unilateral swelling, warmth); avoid deep work on neuropathic feet — gentle holding or light touch only
- Hands and feet (if neuropathy allows) — gentle holding and light compression provides proprioceptive input without deep pressure; some neuropathic patients find light touch more irritating than deeper holding — ask the patient's preference
- Scalp and face (if welcomed) — gentle cranial holds, light temporal massage; ask permission first given alopecia sensitivity
- Closing — gentle grounding holds; allow the patient to rest for several minutes before repositioning; assist with position changes slowly
Adjunct Modalities
- Hydrotherapy: warm packs to shoulder and neck for comfort (confirm sensation is intact); cool cloth to forehead or posterior neck for nausea management; avoid temperature extremes on neuropathic areas
- Remedial exercise (on-table): only if the patient has energy and interest; gentle active ROM of limbs to maintain mobility; deep breathing exercises for relaxation and oxygenation; do not push activity on fatigued patients
Exam Station Notes
- Demonstrate blood count inquiry as the first assessment step — the examiner expects you to ask about recent lab values, treatment timing, and platelet/neutrophil counts
- Show port/line identification and avoidance — verbalize that you will not apply pressure over the device
- Demonstrate pressure modification — state that pressure is scaled to platelet count
- Show IPAC awareness — verbalize that you would postpone treatment if you have any symptoms of illness while the patient is neutropenic
Verbal Notes
- Blood count inquiry: "When was your last chemotherapy treatment, and do you know your most recent blood count results? This helps me plan the safest and most effective session for you today."
- Port/line protection: "I see you have a port (or PICC line) on your chest (or arm). I'm going to stay completely away from that area during our session. If I get too close or anything feels uncomfortable, please let me know right away."
- Neuropathy check: "I understand you've been having some numbness and tingling in your hands (or feet). Before I work on those areas, I want to test how well you can feel my touch — this helps me make sure I use the right amount of pressure in those areas."
- Alopecia sensitivity: "Would you like me to include some work on your scalp and head today, or would you prefer I focus on other areas?"
Self-Care
- Gentle daily walking as energy allows — even brief walks (5–10 minutes) help maintain cardiovascular fitness and reduce deconditioning
- Rest when needed without guilt — cancer-related fatigue is a physiological state, not laziness; give the body permission to rest
- Meticulous hand hygiene and infection avoidance during neutropenic periods — avoid crowds, sick contacts, and raw foods
- Report new or worsening symptoms promptly to the oncology team — particularly fever, unusual bleeding, new shortness of breath, or worsening neuropathy
Key Takeaways
- Chemotherapy is systemic; treatment side effects — not the cancer itself — drive most massage modifications
- Blood counts guide every session: platelet count determines safe pressure (<50,000 = light only; <20,000 = circulatory massage contraindicated); neutrophil count determines infection precautions (ANC <1000 = neutropenic precautions)
- The nadir (7–14 days post-treatment) is the highest-risk period; mid-cycle timing is safest for massage
- Plant alkaloids (vincristine, paclitaxel) cause peripheral neuropathy that reduces sensory feedback — constant pressure verification is essential in affected areas
- Never apply pressure over ports, PICC lines, or central venous catheters — these are absolute avoidance zones
- Anthracyclines (doxorubicin) cause dose-dependent cardiotoxicity — new dyspnea, edema, or chest discomfort requires oncologic referral
- Active cancer is a major DVT risk factor — screen at every session